452 related articles for article (PubMed ID: 15908059)
21. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
22. Relative efficacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation.
De Wals P; Trottier P; Pépin J
Vaccine; 2006 Apr; 24(17):3500-4. PubMed ID: 16517032
[TBL] [Abstract][Full Text] [Related]
23. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision.
Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA
Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine.
De Wals P; Deceuninck G; Boulianne N; De Serres G
JAMA; 2004 Nov; 292(20):2491-4. PubMed ID: 15562128
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.
De Wals P; Deceuninck G; Lefebvre B; Boulianne N; De Serres G
Pediatr Infect Dis J; 2011 Jul; 30(7):566-9. PubMed ID: 21326136
[TBL] [Abstract][Full Text] [Related]
26. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
27. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
28. The Meningitis Vaccine Project.
LaForce FM; Konde K; Viviani S; Préziosi MP
Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec.
De Wals P; Deceuninck G; De Serres G; Boivin JF; Duval B; Remis R; Massé R
Clin Infect Dis; 2005 Apr; 40(8):1116-22. PubMed ID: 15791510
[TBL] [Abstract][Full Text] [Related]
30. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
[TBL] [Abstract][Full Text] [Related]
31. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
[TBL] [Abstract][Full Text] [Related]
32. New frontiers in meningococcal vaccines.
Anderson AS; Jansen KU; Eiden J
Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
[TBL] [Abstract][Full Text] [Related]
33. Quadrivalent meningococcal conjugate vaccines.
Pace D; Pollard AJ; Messonier NE
Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
[TBL] [Abstract][Full Text] [Related]
34. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of meningococcal serogroup C vaccine programmes.
Borrow R; Abad R; Trotter C; van der Klis FR; Vazquez JA
Vaccine; 2013 Sep; 31(41):4477-86. PubMed ID: 23933336
[TBL] [Abstract][Full Text] [Related]
36. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
37. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
Trotter CL; Gay NJ; Edmunds WJ
Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
[TBL] [Abstract][Full Text] [Related]
38. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
39. Meningococcal C conjugate vaccine: the experience in England and Wales.
Campbell H; Borrow R; Salisbury D; Miller E
Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]